Position
Commodore Capital LP in Nurix Therapeutics, Inc.
Back to the book · All holders of NRIX
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$7.89M$18.97 → $15.50
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 2.27M | $43.2M | — | — | — | 2.9% |
| Q1 2026 | 2.27M | $35.3M | $15.50 | −$7.89M | −$0 | 2.0% |